Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ansell

Showing results (171-180 of 194) with videos related to

Pageof 20
Sort By:
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
Journal of Lipid Research|April 3, 2004
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLMohamad Navab, G M Ananthramaiah, Srinivasa T Reddy, et al.
The British Journal of Oral & Maxillofacial Surgery|March 31, 2020
Postoperative risk stratification in oral squamous cell carcinomaJ D McMahon, R Pitts, J Isbister, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanibEvelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
Journal of Thrombosis and Haemostasis : JTH|June 20, 2014
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trialC Christersson, L Wallentin, U Andersson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2012
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumorsHajime Asahina, Yosuke Tamura, Hiroshi Nokihara, et al.
Journal of Applied Microbiology|August 26, 2019
Developments in understanding and applying prebiotics in research and practice-an ISAPP conference paperK P Scott, R Grimaldi, M Cunningham, et al.
Surgery Open Science|October 10, 2022
Safety of maintaining elective and emergency surgery during the COVID-19 pandemic with the introduction of a Protected Elective Surgical Unit (PESU): A cross-specialty evaluation of 30-day outcomes in 9,925 patients undergoing surgery in a University Health BoardT Minto, T Abdelrahman, L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Pageof 20

Showing results (171-180 of 194) with videos related to

Sort By:
Pageof 20
Investigational New Drugs|March 20, 2020
A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFRJames M Cleary, Emiliano Calvo, Victor Moreno, et al.
Journal of Lipid Research|April 3, 2004
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLMohamad Navab, G M Ananthramaiah, Srinivasa T Reddy, et al.
The British Journal of Oral & Maxillofacial Surgery|March 31, 2020
Postoperative risk stratification in oral squamous cell carcinomaJ D McMahon, R Pitts, J Isbister, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanibEvelyn M McKeegan, Peter J Ansell, Gerard Davis, et al.
Journal of Thrombosis and Haemostasis : JTH|June 20, 2014
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trialC Christersson, L Wallentin, U Andersson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2012
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumorsHajime Asahina, Yosuke Tamura, Hiroshi Nokihara, et al.
Journal of Applied Microbiology|August 26, 2019
Developments in understanding and applying prebiotics in research and practice-an ISAPP conference paperK P Scott, R Grimaldi, M Cunningham, et al.
Surgery Open Science|October 10, 2022
Safety of maintaining elective and emergency surgery during the COVID-19 pandemic with the introduction of a Protected Elective Surgical Unit (PESU): A cross-specialty evaluation of 30-day outcomes in 9,925 patients undergoing surgery in a University Health BoardT Minto, T Abdelrahman, L Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2019
Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with GlioblastomaAndrew B Lassman, Lisa Roberts-Rapp, Irina Sokolova, et al.
Pageof 20